Status:
COMPLETED
Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix
Lead Sponsor:
Sokbom Kang
Conditions:
Cervical Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
-list item one, The purpose of this study is to evaluate the overall response rate of belotecan (CKD-602) in recurrent or progressive carcinoma of uterine cervix
Detailed Description
* list item one, to evaluate toxicities of Belotecan * list item two, to evaluate duration of primary response for responding patients * list item three, to evaluate time to disease progression * list...
Eligibility Criteria
Inclusion
- Histologically confirmed, patients with recurrent uterine cervical carcinoma who were unsuitable candidates for curative treatment with surgery and/or radiotherapy.
- One of the following histologic types
- Squamous cell carcinoma
- Adenocarcinoma
- Adenosquamous carcinoma
- Clinically measurable disease
- Performance status of 0, 1, 2 on the ECOG criteria
Exclusion
- Histology of neuroendocrine tumors
- Patient previously treated with topoisomerase-I inhibitor
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00430144
Start Date
January 1 2007
End Date
October 1 2010
Last Update
April 26 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National cancer center
Seoul, South Korea